Daiichi Sankyo has made the development of RNA-based therapeutics and vaccines one of the pillars of its R&D operations and has turned to start-up Depixus to accelerat
Merck & Co has ramped up its involvement in the RNA category, partnering with US biotech Orna Therapeutics in a deal valued at up to $3.5 billion, including $150 million upfront.
Armed with a $100 million second-round financing, CAMP4 Therapeutics is preparing to start the first clinical trial of a drug targeting regulatory RNA (regRNA) molecules that can be used to